Summary of ARQULE INC - Yahoo! Finance

Quotes & Info

Enter Symbol(s):
e.g. YHOO, ^DJI

Symbol Lookup | Financial Search

ARQL > SEC Filings for ARQL > Form 8-K on 11-Jan-2013

All Recent SEC Filings

Show all filings for ARQULE INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ARQULE INC

11-Jan-2013

Other Events, Financial Statements and Exhibits

Item 8.01 Other Events.

On January 11, 2013, ArQule, Inc. (the "Registrant") and Daiichi Sankyo, Co., Ltd. (Daiichi Sankyo") announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer. Daiichi Sankyo was conducting the trial as a licensee and co-developer of tivantinib with the Registrant.

A copy of the press release dated January 11, 2013 summarizing the results is filed as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 - Clinical trial results press release dated January 11, 2013

Add ARQL to Portfolio

Set Alert

Email to a Friend

Get SEC Filings for Another Symbol: Symbol Lookup

Quotes & Info for ARQL - All Recent SEC Filings

Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now

Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.